172
Participants
Start Date
June 30, 2009
Primary Completion Date
July 31, 2014
Study Completion Date
May 31, 2015
Pemetrexed
500 mg/m2 IV given over 10 minutes every 21 days
Bevacizumab
15 mg/kg IV every 21 days
Carboplatin
AUC=5 IV every 21 days
University of Pittsburgh Medical Center, Pittsburgh
Virginia Cancer Institute, Richmond
South Carolina Oncology Associates, PA, Columbia
Spartanburg Regional Medical Center, Spartanburg
Medical University of South Carolina, Charleston
Northeast Georgia Medical Center, Gainesville
Memorial Regional Cancer Center, Hollywood
Mount Sinai Comprehensive Cancer Center, Miami Beach
Aventura Medical Center, Aventura
Holy Cross Hospital, Fort Lauderdale
Collaborative Research Group/ Palm Beach Ins of Hem Onc, Boynton Beach
Watson Clinic Center for Cancer Care and Research, Lakeland
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Family Cancer Center, Memphis
Toledo Community Oncology Program, Toledo
Oncology Hematology Care, Cincinnati
Northern Indiana Cancer Research Consortium, South Bend
RHHP/ Hope Cancer Center, Terra Haute
University of Chicago, Chicago
Genesis Cancer Center, Hot Springs
Northeast Arkansas Clinic, Jonesboro
The Center for Cancer and Blood Disorders, Fort Worth
Mayo Clinic - AZ, Scottsdale
Wilshire Oncology Medical Group, LaVerne
Hematology Oncology Associates of Northern NJ, Morristown
Collaborators (1)
Genentech, Inc.
INDUSTRY
SCRI Development Innovations, LLC
OTHER